Bill > HR2213

This bill seeks to improve the United States' medical supply chain resilience by authorizing the President to negotiate trade agreements with trusted partners to address vulnerabilities exposed during the COVID-19 pandemic. The legislation aims to diversify and strengthen medical supply chains by establishing a framework for reducing trade barriers, protecting intellectual property, expediting cross-border movement of critical medical goods, and fostering international collaboration. Key provisions include allowing the President to enter into "trusted trade partner agreements" with countries that demonstrate commitment to global health security, have reliable trade practices, and provide strong intellectual property protections. The bill requires extensive congressional oversight, including advance notice of negotiations, consultation with congressional committees, and a review process that allows Congress to examine and potentially disapprove proposed agreements. The Trade Representative would be responsible for monitoring compliance with these agreements, with the ability to recommend actions such as suspending or withdrawing agreements if a partner fails to meet its commitments. The ultimate goal is to reduce the United States' dependence on a limited number of medical supply sources, particularly those that might pose national security risks, and create a more robust and flexible medical supply chain capable of responding effectively to future public health emergencies.

Budget and Finance

https://www.congress.gov/bill/119th-congress/house-bill/2213/all-info